form13g12312007.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the
Securities Exchange Act of 1934
(Amendment
No. 7)*
Progenics
Pharmaceuticals, Inc.
------------------------------------------------------------------------------------------------------------
(Name
of
Issuer)
Common
Stock, par value $0.0013 per share
------------------------------------------------------------------------------------------------------------
(Title
of
Class of Securities)
743187106
----------------------------------
(CUSIP
Number)
December
31, 2007
------------------------------------------------------------------------------------------------------------
(Date
of
Event Which Requires Filing of this Statement)
Check
the
appropriate box to designate the rule pursuant to which this Schedule is
filed:
[_] Rule
13d-1(b)
[ ] Rule
13d-1(c)
[X] Rule
13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed
to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the
Notes).
---------------------------------
CUSIP
NO.
743187106
---------------------------------
---------------------------------------------------------------------------------------------------------------------------------
NAME
OF REPORTING PERSON
1.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Paul
J. Maddon, M.D., Ph.D.
---------------------------------------------------------------------------------------------------------------------------------
CHECK
THE APPROPRIATE BOX IF A MEMBER
OF A GROUP
2. (a) [_]
(b) [_]
---------------------------------------------------------------------------------------------------------------------------------
SEC
USE ONLY
3.
---------------------------------------------------------------------------------------------------------------------------------
CITIZENSHIP
OR PLACE OF
ORGANIZATION
4.
United
States of America
---------------------------------------------------------------------------------------------------------------------------------
SOLE
VOTING POWER
5.
NUMBER
OF
1,744,774
SHARES --------------------------------------------------------------------------------------
SHARED
VOTING POWER
BENEFICIALLY 6.
OWNED
BY
None
--------------------------------------------------------------------------------------
EACH
SOLE DISPOSITIVE POWER
7.
REPORTING
1,744,774
PERSON --------------------------------------------------------------------------------------
SHARED
DISPOSITIVE POWER
WITH: 8.
None
---------------------------------------------------------------------------------------------------------------------------------
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY
EACH REPORTING PERSON
9.
1,744,774
---------------------------------------------------------------------------------------------------------------------------------
CHECK
IF THE AGGREGATE AMOUNT IN ROW
(9) EXCLUDES CERTAIN SHARES
10. [_]
---------------------------------------------------------------------------------------------------------------------------------
PERCENT
OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)
11.
5.6
%
---------------------------------------------------------------------------------------------------------------------------------
TYPE
OF REPORTING PERSON
12.
IN
---------------------------------------------------------------------------------------------------------------------------------
Item
1.
(a)
Name of Issuer:
Progenics
Pharmaceuticals, Inc.
(b)
Address of Issuer’s Principal Executive Offices:
777
Old Saw Mill River Road
Tarrytown,
NY 10591
Item
2.
(a)
Name of Person Filing:
Paul
J. Maddon, M.D., Ph.D.
(b)
Address of Principal Business Office or, if none, Residence:
777
Old Saw Mill River Road
Tarrytown,
NY 10591
(c)
Citizenship:
United
States of America
(d)
Title of Class of Securities:
|
Common
Stock, par value $0.0013 per share
|
(e)
CUSIP Number:
743187106
Item
3.
|
If
this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or
(c),
check whether the person filing is a:
|
(a)
Amount Beneficially Owned:
1,744,774
shares, which includes 694,148 shares and 1,050,626 shares that may be acquired
upon exercise of certain options held by reporting person. Excludes 1,000
shares held by reporting person's spouse (the beneficial ownership of which
the
reporting person disclaims) and 90,229 shares
held by a
trust, of which the reporting person’s spouse is the beneficiary; neither the
reporting person nor his spouse has investment control over such
trust.
(b)
Percent of class:
5.6%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote
1,744,774
(ii) Shared
power to vote or to direct the vote
None
(iii) Sole
power to dispose or to direct the disposition of
1,744,774
(iv) Shared
power to dispose or to direct the disposition of
None
Item
5.
|
Ownership
of Five Percent or Less of a Class.
|
Item
6.
|
Ownership
of More than Five Percent on Behalf of Another Person.
|
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security
Being
Reported on by the Parent Holding Company.
|
Item
8.
|
Identification
and Classification of Members of the Group.
|
Item
9.
|
Notice
of Dissolution of Group.
|
N/A
After
reasonable inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
January
31,
2008
/
s/
Paul
J. Maddon, M.D., Ph.D.
Paul
J. Maddon, M.D.,
Ph.D.